Carlyle and SK Capital Partners have announced the expiration of their tender offer to acquire all outstanding common stock of bluebird bio, Inc. The offer, which commenced on March 7, 2025, expired as scheduled at one minute after 11:59 p.m. New York City time on May 29, 2025.
Equiniti Trust Company, LLC advised that a total of 5,868,196 shares were validly tendered and not withdrawn by the expiration time. This represents approximately 59.8% of bluebird’s outstanding shares. All conditions for the offer have been met, and Beacon Merger Sub, Inc. has accepted for payment all shares validly tendered.
The acquisition is expected to be completed on June 2, 2025, through a merger in accordance with Section 251(h) of Delaware’s General Corporation Law without requiring a vote from bluebird stockholders.
Founded in 2010, bluebird bio focuses on gene therapy and has FDA approvals for three therapies. Carlyle is a global investment firm with $453 billion in assets under management as of March 31, 2025. SK Capital is a private investment firm focusing on life sciences and specialty materials sectors.
Investors and media can contact representatives from bluebird bio, Carlyle, and SK Capital for further information.
